KR20160127821A - 다량체 Fc 단백질 - Google Patents

다량체 Fc 단백질 Download PDF

Info

Publication number
KR20160127821A
KR20160127821A KR1020167027644A KR20167027644A KR20160127821A KR 20160127821 A KR20160127821 A KR 20160127821A KR 1020167027644 A KR1020167027644 A KR 1020167027644A KR 20167027644 A KR20167027644 A KR 20167027644A KR 20160127821 A KR20160127821 A KR 20160127821A
Authority
KR
South Korea
Prior art keywords
val
pro
ser
residue
leu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020167027644A
Other languages
English (en)
Korean (ko)
Inventor
파르나즈 팔라-아라니
로버트 안토니 그리핀
데이비드 폴 험프리스
셜리 제인 피터스
브라이언 존 스미스
폴 에드워드 스티븐스
Original Assignee
유씨비 바이오파마 에스피알엘
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB201403915A external-priority patent/GB201403915D0/en
Priority claimed from GB201403914A external-priority patent/GB201403914D0/en
Priority claimed from GBGB1405955.4A external-priority patent/GB201405955D0/en
Priority claimed from GB201412648A external-priority patent/GB201412648D0/en
Application filed by 유씨비 바이오파마 에스피알엘 filed Critical 유씨비 바이오파마 에스피알엘
Publication of KR20160127821A publication Critical patent/KR20160127821A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70535—Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/528—CH4 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/66—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a swap of domains, e.g. CH3-CH2, VH-CL or VL-CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
KR1020167027644A 2014-03-05 2015-03-05 다량체 Fc 단백질 Withdrawn KR20160127821A (ko)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
GB201403915A GB201403915D0 (en) 2014-03-05 2014-03-05 Proteins
GB1403915.0 2014-03-05
GB1403914.3 2014-03-05
GB201403914A GB201403914D0 (en) 2014-03-05 2014-03-05 Proteins
GB1405955.4 2014-04-02
GBGB1405955.4A GB201405955D0 (en) 2014-04-02 2014-04-02 Proteins
GB201412648A GB201412648D0 (en) 2014-07-16 2014-07-16 Proteins
GB1412648.6 2014-07-16
PCT/EP2015/054688 WO2015132365A1 (en) 2014-03-05 2015-03-05 Multimeric fc proteins

Publications (1)

Publication Number Publication Date
KR20160127821A true KR20160127821A (ko) 2016-11-04

Family

ID=52697365

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020167027644A Withdrawn KR20160127821A (ko) 2014-03-05 2015-03-05 다량체 Fc 단백질

Country Status (13)

Country Link
US (1) US20170081406A1 (cg-RX-API-DMAC10.html)
EP (1) EP3114137A1 (cg-RX-API-DMAC10.html)
JP (1) JP6851199B2 (cg-RX-API-DMAC10.html)
KR (1) KR20160127821A (cg-RX-API-DMAC10.html)
CN (1) CN106132994A (cg-RX-API-DMAC10.html)
AU (1) AU2015226101B2 (cg-RX-API-DMAC10.html)
BR (1) BR112016020377A2 (cg-RX-API-DMAC10.html)
CA (1) CA2939201A1 (cg-RX-API-DMAC10.html)
IL (1) IL247246A0 (cg-RX-API-DMAC10.html)
MX (1) MX2016010953A (cg-RX-API-DMAC10.html)
RU (1) RU2016139022A (cg-RX-API-DMAC10.html)
SG (1) SG11201606596PA (cg-RX-API-DMAC10.html)
WO (1) WO2015132365A1 (cg-RX-API-DMAC10.html)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106068274A (zh) 2014-03-05 2016-11-02 Ucb生物制药私人有限公司 多聚体Fc蛋白
SG10201913507SA (en) 2014-05-02 2020-02-27 Momenta Pharmaceuticals Inc Compositions and methods related to engineered fc constructs
GB201511787D0 (en) * 2015-07-06 2015-08-19 Ucb Biopharma Sprl Proteins
GB201513033D0 (en) * 2015-07-23 2015-09-09 Ucb Biopharma Sprl Proteins
IL309260B2 (en) 2015-07-24 2025-01-01 Gliknik Inc Fusion proteins of human protein fragments to create ordered multimeric immunoglobulin FC preparations with enhanced complement binding
RU2018130525A (ru) * 2016-01-27 2020-02-27 Цсл Беринг Ленгнау Аг РЕКОМБИНАНТНЫЕ Fc-МУЛЬТИМЕРЫ IgG
US12391759B2 (en) 2016-03-02 2025-08-19 Momenta Pharmaceuticals, Inc. Methods related to engineered Fc constructs
IL309293A (en) 2016-05-23 2024-02-01 Momenta Pharmaceuticals Inc Compositions and methods relating to engineered FC constructs
CA3026420A1 (en) 2016-06-07 2017-12-14 Gliknik Inc. Cysteine-optimized stradomers
KR20190032392A (ko) 2016-07-22 2019-03-27 글리크닉 인코포레이티드 향상된 fc 수용체 결합을 갖는 규칙적으로 다량체화된 면역글로불린 fc 조성물을 생성하기 위한 인간 단백질 단편의 융합 단백질
BR112019009495A2 (pt) 2016-12-09 2019-08-06 Gliknik Inc métodos de tratamento de distúrbios inflamatórios com compostos de fc multivalentes
CN110650748B (zh) 2017-01-06 2024-01-02 动量制药公司 与经工程改造的Fc构建体相关的组合物和方法
US12024560B2 (en) 2017-03-28 2024-07-02 Lyvgen Biopharma Holdings Limited Therapeutic agents and methods for enhancing immune responses in tumor microenvironment
JP7351835B2 (ja) * 2017-12-14 2023-09-27 ツェー・エス・エル・ベーリング・レングナウ・アクチエンゲゼルシャフト 視神経脊髄炎の処置のための組換えＩｇＧ Ｆｃ多量体
EP3880248A4 (en) * 2018-11-14 2022-08-10 JN Biosciences, LLC MULTIMERIC HYBRID FC PROTEINS FOR IV IG REPLACEMENT
GB201903767D0 (en) * 2019-03-19 2019-05-01 Quadrucept Bio Ltd Multimers, tetramers & octamers
AU2020344164A1 (en) 2019-09-13 2022-04-14 CSL Behring Lengnau AG Recombinant IgG Fc multimers for the treatment of immune complex-mediated kidney disorders
BR112022010096A2 (pt) * 2019-12-06 2022-09-06 CSL Behring Lengnau AG Composições estáveis de multímeros fc
CN115724985A (zh) * 2021-08-27 2023-03-03 三生国健药业（上海）股份有限公司 一种cdc平台抗体
CN117925664B (zh) * 2023-11-29 2025-01-21 上海科锐克医药科技有限公司 用于递送人vegf受体融合蛋白的基因递送载体及其应用
WO2026093188A1 (en) * 2024-10-28 2026-05-07 Sanofi Multimerization domains for the generation of homogenous multimers with immunoglobulin backbone

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2010008578A (es) * 2008-02-08 2010-11-10 Medimmune Llc Anticuerpos anti-receptor 1 de interferon alfa con afinidad reducida al ligando fc.
MX2010010027A (es) * 2008-03-13 2011-05-02 Biotest Ag Agente para tratar enfermedad.
JP2012515556A (ja) * 2009-01-23 2012-07-12 バイオジェン・アイデック・エムエイ・インコーポレイテッド 低下したエフェクタ機能を有する安定化Ｆｃポリペプチドおよび使用方法
EP2760891B1 (en) * 2011-09-26 2018-11-07 JN Biosciences LLC Hybrid constant regions
CA2879814A1 (en) * 2012-08-02 2014-02-06 Jn Biosciences Llc Antibodies or fusion proteins multimerized via cysteine mutation and a mu tailpiece

Also Published As

Publication number Publication date
WO2015132365A1 (en) 2015-09-11
JP2017509335A (ja) 2017-04-06
MX2016010953A (es) 2016-11-29
CN106132994A (zh) 2016-11-16
US20170081406A1 (en) 2017-03-23
EP3114137A1 (en) 2017-01-11
RU2016139022A (ru) 2018-04-25
AU2015226101A1 (en) 2016-08-25
SG11201606596PA (en) 2016-09-29
JP6851199B2 (ja) 2021-03-31
AU2015226101B2 (en) 2019-08-22
CA2939201A1 (en) 2015-09-11
IL247246A0 (en) 2016-09-29
BR112016020377A2 (pt) 2018-01-23

Similar Documents

Publication Publication Date Title
US11352414B2 (en) Multimeric Fc proteins
AU2015226101B2 (en) Multimeric Fc proteins
EP3820569B1 (en) Antibody molecules that bind pd-l1 and cd137
JP2017513481A (ja) 多量体Ｆｃタンパク質
US20180044416A1 (en) Polymeric Fc proteins and methods of screening to alter their functional characteristics
EP3897845A1 (en) Bifunctional molecule directed against human pd-1
JP2022088367A (ja) 共刺激ｔｎｆ受容体に対する二重特異性抗体
IL323895A (en) Bifunctional anti-pd-1/il-7 molecule
WO2017036905A1 (en) Multimeric proteins which bind to human fc-receptors
WO2020165374A1 (en) Bifunctional molecule comprising il-15ra
JP2025535041A (ja) 自己抗体介在疾患の治療における使用のための変異ｔａｃｉ－ｆｃ融合タンパク質
JP7602485B2 (ja) 抗ｃｄ３８抗体および製剤
US20260049141A1 (en) Multifunctional molecule directed against cd28
HK40050345A (en) Antibody molecules that bind pd-l1 and cd137
HK40050345B (en) Antibody molecules that bind pd-l1 and cd137

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20161005

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination